A Phase I/II, Open-label Study to Evaluate the Abscopal Response and Safety of Manganese and Standard-of-care Radiotherapy/ SBRT in Subjects With Metastatic Solid Tumors or Lymphoma

Radiotherapy is a regular care for metastatic solid tumors or lymphoma, and it can induce immunogenic death of tumor cells and a stronger immune response. Sometimes, tumor regression would be observed at sites distant to an irradiated field because of the radiotherapy-induced anticancer immune responses, so-called abscopal response. Manganese has been confirmed to activate innate immune and function as anticancer immunoadjuvant in pre-clinical studies. This study is designed to assess the abscopal response and safety of combined therapy of manganese and radiotherapy in patients with metastatic solid tumors or lymphoma.

Start Date06 May 2021

Sponsor / Collaborator

Chinese People's Liberation Army General Hospital

NCT03989336

/ CompletedPhase 2IIT

A Randomized, Single-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Relapsed/Refractory Ovarian Cancer

Ovarian cancer is the most lethal gynecological cancer and the 5th leading cause of cancer death in women. Platinum chemotherapy has been widely adopted as a standard treatment for advanced ovarian cancer, the response rates in patients with relapsed/refractory ovarian cancer is unacceptably low. PD-1 blockade has been developed to a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This two-arm, phase I/II study is designed to assess the safety and efficacy of combined therapy of anti-PD-1 antibody and chemotherapy with or without Manganese priming.

Start Date23 Dec 2020

Sponsor / Collaborator

Chinese People's Liberation Army General Hospital

NCT04119843

/ CompletedPhase 3

A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients With Known or Suspected Focal Liver Lesions and Severe Renal Impairment

The overall objective of this study is to evaluate the safety and diagnostic efficacy of Mangoral in liver MRI in participants with known or suspected focal liver lesions and severe renal impairment. The diagnostic efficacy of Mangoral will be assessed in terms of visualization of detected focal liver lesions in combined MRI (CMRI: combined Mangoral-enhanced and unenhanced MRI) compared to unenhanced MRI.

Start Date19 Feb 2020

Sponsor / Collaborator

Ascelia Pharma AB

100 Clinical Results associated with Manganese Chloride

100 Translational Medicine associated with Manganese Chloride

100 Patents (Medical) associated with Manganese Chloride

1,697

Literatures (Medical) associated with Manganese Chloride

01 Jan 2026·FUEL

Catalytic performance of transition metal molybdates in accelerated oxidative desulfurization

Author: Eseva, E. ; Anisimov, A. ; Cherednichenko, K. ; Grafov, O. ; Akopyan, A. ; Levin, I. ; Latypova, S.

New challenges are emerging for improving desulfurization technologies due to the introduction of heavy oil feedstock into fuel energy.In this work, catalysts based on Fe, Co, Mn and Bi molybdates are tested in the process of aerobic oxidation of sulfur-containing compounds of the thiophene series in an alkane medium.The catalysts are characterized by a set of physicochem. methods: XRD, FTIR, TGA, low-temperature nitrogen adsorption-desorption, SEM, TEM, NH₃-TPD, H₂-TPR, XPS.A comparative assessment of the catalytic activity of the obtained molybdates in the oxidation reaction of a model mixture of dibenzothiophene (DBT) in dodecane with air is carried out.It is shown that iron molybdate has the highest activity, in which an important role is played by excess molybdenum in the form of trioxide MoO₃.In the presence of a biphasic catalyst, 100 % conversion of DBT is achieved in 15 min at 170 °C.The specific activity is 172 mmol*g^-1*h^-1 (170 °C, 10 min).A possible reaction mechanism based on the activation of O₂ and the generation of active species in the presence of the Fe³⁺/Fe²⁺ redox couple, and the oxidation of the sulfur substrate at molybdenum sites has been proposed.The high efficiency of the catalyst is confirmed by the results of aerobic oxidative desulfurization of non-hydrotreated vacuum gas oil with a high sulfur content (18 000 ppm), achieving more than 85 % desulfurization degree.

01 Dec 2025·MEDICAL PHYSICS

Efficient estimation of gadolinium‐based contrast agent concentration using transient‐state keyhole MR‐STAT

Article

Author: Fuderer, Miha ; Xu, Fei ; Versteeg, Edwin ; van der Kemp, Wybe J. M. ; van den Berg, Cornelis A. T. ; Sbrizzi, Alessandro ; Liu, Hongyan ; van den Heide, Oscar

Abstract:

Background:

Fast quantitative MRI (qMRI) techniques have emerged to quantify multiple tissue parameters from a single acquisition in clinically feasible scan times. To integrate fast qMRI techniques into a clinical MRI protocol, one needs to consider imaging after injection of a contrast agent (e.g., dynamic contrast‐enhanced [DCE] imaging). However, fully repeating the multi‐parametric scan after the injection requires lengthy scan times, which are impractical for tracking the contrast agent concentration.

Purpose:

This work aimed to develop and validate an accelerated multi‐parametric method capable of estimating the concentration of Gadolinium‐based contrast agents (GBCAs) in a more time‐efficient way.

Methods:

We designed an accelerated 2D Magnetic Resonance Spin TomogrAphy in Time‐domain (MR‐STAT) protocol and tested it on a 3T MRI scanner. This is achieved by combining transient‐state acquisitions with Cartesian keyhole‐based acceleration. Based on the reconstructed T1 values, GBCA concentrations were quantified in phantoms containing water, manganese chloride, and five different concentrations of gadobutrol (Gadovist), ranging from 0.05 to 0.9 mM. Linear regression analysis between the estimated GBCA concentration and the reference values was performed to assess the accuracy. The GBCA concentration quantification method was then applied for synthetic patient data and a hybrid human/phantom study to demonstrate the feasibility of this method.

Results:

The accelerated MR‐STAT protocol, with an undersampling factor of 4, provided accurate T1 , T2, and GBCA concentration measurements. Estimated GBCA concentrations were in a strong linear relationship with reference values, with a slope and intercept on simple linear regression analysis of 1.034 and 0.009, respectively.

Conclusion:

We present a multi‐parametric approach for quantitatively assessing the concentration of gadolinium in vitro and in a hybrid in vivo/in vitro controlled setup using the accelerated MR‐STAT protocol. The concentration of gadobutrol in the range of 0.05–0.9 mM could be measured in a clinically applicable scan time using the proposed method, but needs further in vivo validation.

01 Dec 2025·APPLIED CATALYSIS B-ENVIRONMENTAL

Redox-oriented anchoring of CeO2 over nanostructured MnCo-spinel: Strong oxide-support interaction for enhanced toluene combustion

Author: Pan, Bingcai ; Huang, Qianlin ; Zhang, Weiming ; Chen, Xi ; Lv, Lu

Developing efficient and robust earth-abundant catalysts remains a critical challenge for volatile organic compounds (VOCs) combustion.Herein, we propose a redox-oriented anchoring strategy to fabricate a nanostructured MnCo@CeO₂ heterostructure catalyst for efficient low-temperature toluene oxidationThis approach involves the in situ anchoring of CeO₂ onto Mn₃[Co(CN)₆]₂ (MnCoPBA, a metal-organic framework), followed by a pyrolysis process.Both exptl. and theor. investigations reveal that MnCoPBA not only serves as a template to facilitate the in situ construction of abundant heterostructure interfaces to maximize surface active sites, but also functions as an oxidant to strengthen the strong oxide-support interaction (SOSI) between CeO₂ and the MnCo support.The SOSI effect enables effective electron transfer from CeO₂ to MnCo via Co-O-Ce moieties, facilitating the formation of electron-rich MnCo and oxygen vacancies.Consequently, O₂ mols. adsorb more readily onto these oxygen vacancies and undergo activation through electron transfer from electron-rich MnCo, generating highly reactive oxygen species.Moreover, SOSI-mediated electron redistribution reduces the electron cloud d. around the O atom in Co-O-Ce moieties, thereby enhancing surface lattice oxygen activation.In turn, it significantly accelerates the generation and mineralization of intermediate species, facilitating the rapid deep oxidation of toluene mols. via the Mars-van Krevelen mechanism.Consequently, the MnCo@CeO₂ catalyst exhibits superior low-temperature activity (T₉₀ _% = 228°C at a space velocity of 30000 mL g^-1 h^-1) and robust stability even in the presence of 5 vol% water.This work offers a new direction for the rational design and optimization of catalysts for controlling VOCs emissions.

News (Medical) associated with Manganese Chloride

10 Apr 2026

·www.biospace.com

Annual Report 2025: Orviglance NDA submitted to the FDA, PDUFA-date set for July 2026

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / April 9, 2026 / Ascelia Pharma (STO:ACE) today published its Annual Report 2025, which is now available on the company’s website . Magnus Corfitzen, CEO, Ascelia Pharma, says: Following the Orviglance New Drug Application (NDA) submission in September 2025, we received the US Food and Drug Administration (FDA) Day 74 letter in November, which formally accepted our NDA for review, aiming for a decision by 3 July 2026 as the PDUFA date. This milestone underscores the quality and completeness of our submission and marks a critical step toward making Orviglance available to patients with severe kidney impairment who need a contrast enhanced liver MRI procedure. We look forward to continuing to work with the FDA throughout the review process. The NDA submission is based on the successful completion of the development program, which includes nine clinical studies with consistent positive efficacy and safety results. In our Phase 3 study, SPARKLE, Orviglance significantly improved visualization of focal liver lesions in patients with impaired kidney function, meeting the primary endpoint with statistical significance for all three readers (<0.001). We have a cash runway into Q4 2026, well beyond the expected FDA approval date of Orviglance. This follows a directed share issue in September 2025, raising SEK 30 million before costs, which strengthened our balance sheet based on the inbound interest expressed by investors. Our partnering process continues to progress, and multiple potential partners demonstrate strong strategic interest. With the regulatory timeline now firmly established, these dialogues have gained additional momentum and clarity, and we remain well positioned to secure a partnering agreement. About us Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates - Orviglance and Oncoral - in development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit . Contacts Magnus Corfitzen, CEO Email: moc@ascelia.com Tel: +46 735 179 118 Anton Hansson, CFO Email: anton.hansson@ascelia.com Tel: +46 735 179 113 This information was submitted for publication, through the agency of the contact persons set out above. This information is information that Ascelia Pharma is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-09 17:00 CEST. Attachments Ascelia Pharma Annual Report 2025 SOURCE: Ascelia Pharma View the original press release on ACCESS Newswire

Phase 3NDA

30 Mar 2026

·www.biospace.com

Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026

MALMÖ, SE / ACCESS Newswire / March 27, 2026 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that an abstract with an evaluation of the detection of focal liver lesions with Orviglance contrast agent from two phase 2 studies has been accepted for oral presentation at the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Annual Meeting, taking place 9-12 June in Montpellier, France. The abstract titled "Diagnostic Value of Manganese-Based Contrast Agent (ACE-MBCA) vs Unenhanced MRI in Liver Lesion Detection: Re-analysis of STAR Study Images from Two Phase II Clinical Trials", demonstrated that Orviglance significantly improves the detection of focal liver lesions compared to unenhanced MRI. The findings underline the potential of Orviglance as a new contrast agent for liver MRI. "We are excited that an abstract with Orviglance data has been selected for oral presentation at ESGAR, one of the leading global forums for innovation in gastrointestinal and abdominal imaging. This recognition highlights the growing scientific interest in manganese-based contrast agents", says Andreas Norlin, CSO of Ascelia Pharma. Presenting author: Dr. D. Geisel (Charité - Universitätsmedizin Berlin, Germany) Timing of presentation: 9 June 2026, 10:00 - 10:30 CET Ascelia Pharma has submitted the New Drug Application (NDA) for Orviglance to the US Food and Drug Administration (FDA) with expected approval date of 3 July 2026. Contacts Magnus Corfitzen, CEO Email: moc@ascelia.com Tel: +46 735 179 118 Anton Hansson, CFO Email: anton.hansson@ascelia.com Tel: +46 735 179 113 This information was submitted for publication, through the agency of the contact persons set out above. About us Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates - Orviglance and Oncoral - in development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit About Orviglance Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A clinical program of nine studies, including the pivotal global Phase 3 study SPARKLE, has successfully been completed with strong and consistent efficacy and safety results. The New Drug Application (NDA) has been submitted to the FDA. Attachments ASCELIA PHARMA ANNOUNCES ACCEPTANCE OF ORVIGLANCE DATA FOR ORAL PRESENTATION AT THE ANNUAL RADIOLOGY CONGRESS ESGAR 2026 SOURCE: Ascelia Pharma View the original press release on ACCESS Newswire

Phase 2Orphan DrugPhase 3Clinical ResultNDA

23 Dec 2024

·www.accesswire.com

Ascelia Pharma Patent Granted in China for Second Generation Orviglance

MALMÖ, SWEDEN / ACCESSWIRE / December 23, 2024 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the Chinese patent authorities have granted patent protection for the second-generation Orviglance®The new patent covers the effervescent tablet formulation of Orviglance. This formulation makes it even easier for patients and health care professionals to use the product. This patent protection until 2040 in China further strengthens the value proposition of the Orviglance franchise.ContactsMagnus Corfitzen, CEOEmail: [email protected]Tel: +46 735 179 118Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)Email: [email protected]Tel: +46 735 179 116This information was submitted for publication, through the agency of the contact persons set out above.About usAscelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates - Orviglance and Oncoral - in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.About OrviglanceOrviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A clinical program of nine studies, including the pivotal global Phase 3 study SPARKLE, has successfully been completed with strong and consistent efficacy and safety results.AttachmentsAscelia Pharma Patent Granted in China for Second Generation OrviglanceSOURCE: Ascelia PharmaRelated Documents:

Phase 3Orphan Drug

100 Deals associated with Manganese Chloride

External Link

KEGG	Wiki	ATC	Drug Bank
D04852	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Contrast agents	Japan	Kenei Pharmaceutical Co Ltd.	20 Apr 2006
Contrast agents	Japan	Meiji Seika Pharma Co., Ltd.	20 Apr 2006
Gastrointestinal Diseases	Japan	Kenei Pharmaceutical Co Ltd.	20 Apr 2006
Nutrition Disorders	United States	Hospira, Inc.	26 Jun 1986

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Renal Insufficiency	NDA/BLA	United States	Ascelia Pharma AB	03 Sep 2025
Liver Diseases	Phase 3	United States	Ascelia Pharma AB	19 Feb 2020
Liver Diseases	Phase 3	Argentina	Ascelia Pharma AB	19 Feb 2020
Liver Diseases	Phase 3	Colombia	Ascelia Pharma AB	19 Feb 2020
Liver Diseases	Phase 3	Germany	Ascelia Pharma AB	19 Feb 2020
Liver Diseases	Phase 3	Italy	Ascelia Pharma AB	19 Feb 2020
Liver Diseases	Phase 3	Mexico	Ascelia Pharma AB	19 Feb 2020
Liver Diseases	Phase 3	Poland	Ascelia Pharma AB	19 Feb 2020
Liver Diseases	Phase 3	Russia	Ascelia Pharma AB	19 Feb 2020
Liver Diseases	Phase 3	Sweden	Ascelia Pharma AB	19 Feb 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03989336 (ASCO 12020 \| ASCO 22020) Manual	Phase 2	Ovarian Cancer Last line	27	nab-paclitaxel+ cisplatin+MnCl2+Sintilimab	qnwvupcaxu(mregsboryt) = The most common AEs are hematological toxicity (87%), nausea (56%) and vomiting (47%) in both two cohorts. fxwxbsvbyq (tawrsrykmm )	Positive	25 May 2020
				cisplatin+nab-paclitaxel+Sintilimab

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis